CLARITY PHARMACEUTICALS LIMITED (CU6)
Share Price Analysis and Chart

18/03/2026

1

Speculative Buy

$6.40

104.47%

Clarity Pharmaceuticals has presented key findings from the Co-PSMA study to the European Association of Urology Conference, with the full data set confirming the detection of early stage BCR, particularly in men with very low PSA levels consistent with low tumour burden.

Bell Potter believes the stage is now set for a read-out from the approval study for AMPLIFY. The Co-PSMA data, along with data from COBRA and anticipated findings from AMPLIFY will form the basis for submitting a new drug application to the US FDA.

The broker notes the company is well funded with cash in excess of $226m. Speculative Buy rating and $6.40 target.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -18.70 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -16.60 cents.

19/02/2026

1

Buy

$9.00

187.54%

Canaccord Genuity reiterates its Buy rating and $9.00 target following the release of Co-PSMA trial results, which the broker describes as clinically meaningful.

The head-to-head study showed 64Cu-SAR-bisPSMA detected 78% of lesions versus 36% for 68Ga-PSMA-11, with statistically superior mean lesions per patient and a 44% change in planned management.

Canaccord believes the data reinforces 64Cu-SAR-bisPSMA as a clinically superior second-generation PSMA PET tracer in biochemical recurrent prostate cancer, particularly at low PSA levels where detection is critical for salvage radiotherapy decisions.

An estimated circa 150k additional patients could benefit, supporting incremental US$250m peak sales and total peak sales of US$750–800m, which are already incorporated in forecasts. 

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -26.90 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -34.60 cents.